Impact of Angiotensin I-Converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Progression-Free Survival and Overall Survival in Patients With Non-small Cell Lung Cancer

被引：0
|
作者：
Feng, Yun [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai, Peoples R China
来源：
CHEST | 2016年 / 149卷 / 04期
关键词：
D O I：
10.1016/j.chest.2016.02.323
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：310A / 310A
页数：1
相关论文
共 50 条
  • [41] The impact of renin-angiotensin system, angiotensin I converting enzyme (insertion/deletion), and angiotensin II type 1 receptor (A1166C) polymorphisms on breast cancer survival in Iran
    Namazi, Soha
    Daneshian, Arghavan
    Mohammadianpanah, Mohammad
    Jafari, Peyman
    Ardeshir-Rouhani-Fard, Shirin
    Nasirabadi, Shiva
    [J]. GENE, 2013, 532 (01) : 125 - 131
  • [42] No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers:: A collaborative transplant study report
    Opelz, Gerhard
    Zeier, Martin
    Laux, Gunter
    Morath, Christian
    Doehler, Bernd
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (11): : 3257 - 3262
  • [43] Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore
    Koh, WP
    Yuan, JM
    Van Den Berg, D
    Lee, HP
    Yu, MC
    [J]. CARCINOGENESIS, 2005, 26 (02) : 459 - 464
  • [44] Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
    Memmott, Regan M.
    Wolfe, Adam R.
    Carbone, David P.
    Williams, Terence M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : 1086 - 1098
  • [45] Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer
    Imai, Hisao
    Mori, Keita
    Wakuda, Kazushige
    Ono, Akira
    Akamatsu, Hiroaki
    Shukuya, Takehito
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    [J]. ANNALS OF THORACIC MEDICINE, 2015, 10 (01) : 61 - 66
  • [46] Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers are Associated With Improved Amputation Free Survival in Chronic Limb-threatening Ischemia
    Elsayed, Nadin
    Clouse, Darrin
    Motaganahalli, Raghu L.
    Malas, Mahmoud
    [J]. JOURNAL OF VASCULAR SURGERY, 2023, 78 (03) : E58 - E58
  • [47] Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer
    Yoshida, Yosuke
    Kaneko, Masayuki
    Narukawa, Mamoru
    [J]. PHARMACEUTICAL MEDICINE, 2021, 35 (02) : 81 - 92
  • [48] Impact of Advantage in Tumor Response on the Correlation Between Progression-Free Survival and Overall Survival: Meta-Analysis of Clinical Trials in Patients with Advanced Non-Small Cell Lung Cancer
    Yosuke Yoshida
    Masayuki Kaneko
    Mamoru Narukawa
    [J]. Pharmaceutical Medicine, 2021, 35 : 81 - 92
  • [49] Angiotensin-converting enzyme inhibitor prescription is associated with decreased progression-free survival (PFS) and overall survival (OS) in patients with lung cancers treated with PD-1/PD-L1 immune checkpoint blockers.
    Medjebar, Soleine
    Richard, Corentin
    Fumet, Jean-David
    Malo, Julie
    Elkrief, Arielle
    Blais, Normand
    Tehfe, Mustapha
    Florescu, Marie
    Boidot, Romain
    Truntzer, Caroline
    Routy, Bertrand
    Ghiringhelli, Francois
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Angiotensin-Converting Enzyme Inhibitors Provide Better Long-Term Survival Benefits to Patients With AMI Than Angiotensin II Receptor Blockers After Survival Hospital Discharge
    Choi, In Suck
    Park, Ie Byung
    Lee, Kiyoung
    Ahn, Tae Hoon
    Kim, Ju Han
    Ahn, Youngkeun
    Chae, Sung-Chull
    Kim, Hyo-Soo
    Kim, Young Jo
    Cho, Myeong Chan
    Kim, Chong Jin
    Jeong, Myung Ho
    Lee, Dae Ho
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2019, 24 (02) : 120 - 129
12345